Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212

Stock Track

04/17

Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.

The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.

Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1197879920"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197879920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197879920?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197879920","market":"sg","top_or_hot":-1,"title":"Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212","media":"Stock Track","content":"<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-17 13:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君實生物","start_time":0,"source_url":"","article_id":"1197879920","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197879920","pubTimestamp":1776404469,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"个股赛道|君实生物盘中暴涨5.01%，JS207、JS212获AACR临床数据预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}